Heptares doses first subject in Alzheimer’s drug trial
admin 1st September 2017 Uncategorised 0London, UK-based Heptares Therapeutics says the first healthy subject has now been dosed with its first-in-class, selective muscarinic M4 receptor agonist HTL0016878 in a Phase I clinical study.
More: Heptares doses first subject in Alzheimer’s drug trial
Source: News